2022
Towards development of disease-modifying therapy for Alzheimer's disease using redox chemical biology pathways
Lipton S. Towards development of disease-modifying therapy for Alzheimer's disease using redox chemical biology pathways. Current Opinion In Pharmacology 2022, 66: 102267. PMID: 35870288, PMCID: PMC9509422, DOI: 10.1016/j.coph.2022.102267.Peer-Reviewed Original ResearchConceptsAlzheimer's diseaseDisease-modifying therapiesPotential therapeutic efficacySevere side effectsPotential therapeutic targetCerebral organoid modelTranscription factor Nrf2Absence of diseaseNMDA typeGlutamate receptorsDisease processSide effectsTherapeutic targetTransgenic miceTherapeutic efficacyNeurodegenerative disordersNormal tissuesDiseaseFactor Nrf2Organoid modelsProtein S-nitrosylationS-nitrosylationProtein Keap1TherapyNrf2
1996
Elevated Glutamate Levels in the Vitreous Body of Humans and Monkeys With Glaucoma
Dreyer E, Zurakowski D, Schumer R, Podos S, Lipton S. Elevated Glutamate Levels in the Vitreous Body of Humans and Monkeys With Glaucoma. JAMA Ophthalmology 1996, 114: 299-305. PMID: 8600890, DOI: 10.1001/archopht.1996.01100130295012.Peer-Reviewed Original ResearchConceptsExcitatory amino acid glutamateRetinal ganglion cellsAmino acid glutamateVitreous bodyGlaucomatous eyesGanglion cellsGlutamate levelsRetinal ganglion cell neuronsOptic nerve damageGroup of patientsElevated glutamate levelsGanglion cell neuronsLevels of glutamateEyes of monkeysNerve damageControl eyesVisual dysfunctionNonglaucomatous eyesCataract extractionPosterior capsuleInadvertent ruptureDisease processGlaucomaCell neuronsPatients